Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

NCT04337827 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Post-transplant Lymphoproliferative Disorder

Interventions

DRUG: Rituximab
DRUG: Acalabrutinib
DIAGNOSTIC_TEST: CT scans

Sponsor

Deepa Jagadeesh